NASDAQ:EOLS - Evolus Stock Price, Forecast & News

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus Inc (NASDAQ:EOLS) released its quarterly earnings results on Monday, November, 4th. The company reported ($0.78) earnings per share for the quarter, topping analysts' consensus estimates of ($1.33) by $0.55. The business earned $13.17 million during the quarter, compared to analyst estimates of $5.18 million. View Evolus' Earnings History.

Evolus is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Evolus.

Evolus will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Evolus updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $34-35 million, compared to the consensus revenue estimate of $31.8 million.

10 equities research analysts have issued 12-month price objectives for Evolus' shares. Their forecasts range from $13.00 to $37.00. On average, they anticipate Evolus' share price to reach $26.40 in the next year. This suggests a possible upside of 172.4% from the stock's current price. View Analyst Price Targets for Evolus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus.

News headlines about EOLS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Evolus earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Evolus.

Evolus saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,560,000 shares, an increase of 15.1% from the January 15th total of 5,700,000 shares. Based on an average daily trading volume, of 638,300 shares, the days-to-cover ratio is presently 10.3 days. Currently, 29.4% of the company's stock are short sold. View Evolus' Current Options Chain.

Some companies that are related to Evolus include Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Endonovo Therapeutics (ENDV), NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA), Enanta Pharmaceuticals (ENTA), Dermira (DERM) and ImmunoGen (IMGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA), JD.Com (JD) and Canopy Growth (CGC).

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (7.88%), Cadian Capital Management LP (1.52%), Goldman Sachs Group Inc. (1.44%), State Street Corp (0.89%), Point72 Asset Management L.P. (0.62%) and Voss Capital LLC (0.28%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik. View Institutional Ownership Trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Raymond James Financial Services Advisors Inc., Bank of America Corp DE, B. Riley Wealth Management Inc., Advisor Group Inc., Victory Capital Management Inc., Victory Capital Management Inc. and Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Corp Alphaeon, Lauren P Silvernail and Rui Avelar. View Insider Buying and Selling for Evolus.

EOLS stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Goldman Sachs Group Inc., Point72 Asset Management L.P., Cadian Capital Management LP, Voss Capital LLC, State Street Corp, Bank of New York Mellon Corp and Virtu Financial LLC. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank and Vikram Malik. View Insider Buying and Selling for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $9.69.

Evolus has a market capitalization of $323.84 million. The company earns $-46,870,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Evolus employs 70 workers across the globe.View Additional Information About Evolus.

The official website for Evolus is http://www.evolus.com/.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]